The estimated Net Worth of Venkatesh Srinivasan is at least $150 Thousand dollars as of 1 May 2024. Venkatesh Srinivasan owns over 2,500 units of Sutro Biopharma Inc stock worth over $150,387 and over the last 2 years Venkatesh sold STRO stock worth over $0.
Venkatesh has made over 3 trades of the Sutro Biopharma Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Venkatesh exercised 2,500 units of STRO stock worth $11,525 on 1 May 2024.
The largest trade Venkatesh's ever made was exercising 21,250 units of Sutro Biopharma Inc stock on 11 April 2024 worth over $97,963. On average, Venkatesh trades about 5,750 units every 12 days since 2023. As of 1 May 2024 Venkatesh still owns at least 32,622 units of Sutro Biopharma Inc stock.
You can see the complete history of Venkatesh Srinivasan stock trades at the bottom of the page.
Venkatesh's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund, and Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Sutro Biopharma Inc executives and other stock owners filed with the SEC include: